Bowl of Hygieia. Olomouc, CZ. Michal Maňas CCA-SA 2.5
Nanobiotix - in an ETNP partnership with the CLARA Cancer Research Cluster (Cancéropôle Lyon Auvergne Rhône-Alpes) - organised the Nano- prelude to World Cancer Day. Slides and texts of the Conference's NanoMedicine-themed webcast (from Friday 1 February 2013) are now viewable.
Dr. Amaury Martin's (Secretary General, CLARA) conference component includes considerations re dangers of novel products and risk behaviours.
Dr. Laurent Lévy (Vice-Chair, ETPN; CEO, Nanobiotix) highlights the significant differentiating impact of radio-enhancing nano-modalities in oncological treatments - including expected decreased toxicity and improved efficiencies.
Pr. Dr. Bo Lu (Radio-Oncology|Molecular Biology|Translational Research, Thomas Jefferson University) discusses amelioration and reduction of therapy-related toxicities in the context of radiation/chemotherapy limitations and anticipated patient outcomes during on-going NanoXRay clinical trials. In his component, Dr Lu proposes the possibility of combined nano-radio-immunotherapy applications - a novel strategy still in the proof-of-concept phase.
Pr. Elias Fattal's (CNRS-UMR, Institut Galien Paris-Sud, Université Paris Sud, UFR de Pharmacie) toxicology segment encompasses issues surrounding innovative efficiency while emphasising reduced toxicity of an inherent safe-by-design nano-drug development approach.
Disclosure: LLP holds no financial position nor possesses any vested interest in Nanobiotix SA (NANO:FP).